NCT00867113 · OUTCOME
Kaplan-Meier Estimates for Overall Survival (OS) up to 60 Months
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) · Source last updated 2018-03-14
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline up to appoximately 60 months
What was measured
Overall survival was defined as the time from the date of the first dose of study drug to the date of death. Subjects who were alive at the time of discontinuation/completion of the study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment. Full analysis set.
Groups in this outcome
Imatinib
All subjects received in tablet form imatinib (STI571) 400 mg once daily.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Imatinib | 91 |
|---|
Reported measurements
12 months
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Imatinib | 100.00 | Not reported | 100.00 | 100.00 | Not reported |
|---|
18 months
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Imatinib | 100.00 | Not reported | 100.00 | 100.00 | Not reported |
|---|
24 months
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Imatinib | 98.0 | Not reported | 86.4 | 99.7 | Not reported |
|---|
36 months
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Imatinib | 98.0 | Not reported | 86.4 | 99.7 | Not reported |
|---|
48 months
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Imatinib | 98.0 | Not reported | 86.4 | 99.7 | Not reported |
|---|
60 months
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Imatinib | 93.8 | Not reported | 82.0 | 98.0 | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 100.00
- upper Limit
- 100.00
- value
- 100.00
- title
- 12 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 100.00
- upper Limit
- 100.00
- value
- 100.00
- title
- 18 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 86.4
- upper Limit
- 99.7
- value
- 98.0
- title
- 24 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 86.4
- upper Limit
- 99.7
- value
- 98.0
- title
- 36 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 86.4
- upper Limit
- 99.7
- value
- 98.0
- title
- 48 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 82.0
- upper Limit
- 98.0
- value
- 93.8
- title
- 60 months
- description
- Overall survival was defined as the time from the date of the first dose of study drug to the date of death. Subjects who were alive at the time of discontinuation/completion of the study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment. Full analysis set.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- All subjects received in tablet form imatinib (STI571) 400 mg once daily.
- id
- OG000
- title
- Imatinib
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- Baseline up to appoximately 60 months
- title
- Kaplan-Meier Estimates for Overall Survival (OS) up to 60 Months
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle